Emerging Drug Developer: Tolerx
Holding promising Phase II data for a monoclonal antibody lined up for a late-stage race to the FDA, Tolerx found itself in the sweet spot of biotech deal making. And GlaxoSmithKline was just one of a number of companies to make a bid for it. For Tolerx CEO Douglas Ringler, the $760 million deal they struck gives the company enough cash to make it all the way through to a BLA. But there's little time for relaxation. Tolerx is engaged in a competitive race to get its CD3 program all the way to the FDA. And it plans to be first. Article